{"id":"W4206124890","doi":"10.1200/jco.2021.39.15_suppl.4072","title":"Pembrolizumab (pembro) versus placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the randomized, phase 3 KEYNOTE-240 study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Sorafenib; Placebo; Interim analysis; Clinical trial; Internal medicine; Hepatocellular carcinoma; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001521079,0.0008452056,0.001626224,0.0003442905,0.0002594666,0.0007267853,0.0004726235,0.0007813761,0.003470105],"category_scores_gemma":[0.001589748,0.000464798,0.00129798,0.0004390158,0.0004876544,0.0008324494,0.0004166537,0.001766193,0.0004263115],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006867452,"about_ca_system_score_gemma":0.0007447259,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007136937,"about_ca_topic_score_gemma":0.002226297,"domain_scores_codex":[0.9995265,0.0002622459,0.00003749553,0.00007742769,0.00003275363,0.00006354551],"domain_scores_gemma":[0.9993526,0.0001727477,0.0002184138,0.00003421777,0.00002591037,0.0001961813],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9490693,0.003816337,0.002059115,0.0009037686,0.001404265,0.00005959326,0.00006751152,0.0006337469,0.003817419,0.00009193641,0.001236514,0.03684059],"study_design_scores_gemma":[0.8157554,0.1647282,0.01406403,0.0001006027,0.001692376,0.0001442606,0.00004412975,0.0006873935,0.0008227299,0.0002197108,0.001722331,0.00001884739],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9865732,0.007952837,0.000499748,0.00047721,0.0002401758,0.001396192,0.001355504,0.00008473702,0.001420364],"genre_scores_gemma":[0.9941065,0.002232142,0.0005162284,0.000397112,0.0001427696,0.001031243,0.0008044743,0.000008267356,0.0007612112],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003470105,"threshold_uncertainty_score":0.0116086,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1663976390248904,"score_gpt":0.3974421513583694,"score_spread":0.2310445123334791,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}